Be the first person to write a business review for Actelion Pharmaceuticals UK Ltd.

ActivX Biosciences figures that the more you know about protein kinases, the easier it will be to inhibit them. That's the basis of its main product: a platform to profile protein kinases -- enzymes that regulate cell's signaling pathways. Its KiNativ platform has been launched for use by pharmaceutical and biotechnology companies as they develop the kinase inhibitors expected to make drug breakthroughs. The company also has its own pipeline of drug candidates in development, including one in trials for the treatment of Type-2 diabetes. Japanese drugmaker Kyorin Pharmaceutical, with whom ActivX had collaborated since 2002, bought the company in 2005 for $21 million.

Acurian hopes you can help them find a cure for everything from cancer to anxiety disorders. Acurian company matches up biotech, pharmaceutical, and medical device companies with patients interested in participating in clinical trials for experimental and innovative therapies. The company's website allows interested patients to register their ailments and express their willingness to participate. All this has helped Acurian develop a database of over 50 million interested people, which it connects with about 60 pharma and biotech companies. The company also develops software to help contract research organizations (CROs) manage and track the results of clinical trials.

Acusphere, Inc. is a specialty pharmaceutical company that develops drugs and formulations of existing drugs using its porous microparticle technology. This technology enables the Company to control the size and porosity of particles, including nanoparticles and microparticles, so that the particles can be customized to address the delivery needs of a variety of drugs. These product candidates include Imagify (perflubutane polymer microspheres for delivery in an injectable suspension, formerly known as AI-700), a cardiovascular drug for the detection of coronary artery disease; Hydrophobic Drug Delivery System (HDDS), which converts drugs that do not dissolve well in water into microparticles or nanoparticles of the drugs embedded in small microparticles; and Pulmonary Drug Delivery System (PDDS).

Adherex Technologies researches and develops cancer treatments. One of its lead drug candidates targets a tumor's blood supply and makes those blood vessels weak and leaky by disrupting a key protein. Other potential therapies could make cancer cells more vulnerable to anti-cancer drugs or help prevent hearing loss in children undergoing certain types of chemotherapy. Adherex Technologies' pipeline is strongly based on compounds that disrupt cadherins, proteins that adhere like molecules together in cell adhesion. Southpoint Capital Advisors own a controlling stake in the company.

Adnexus Therapeutics, Inc. engages in the discovery, development, and commercialization of Adnectins biologics/medicines in the United States. The company’s product candidates include Angiocept/CT-322, an anti-angiogenesis agent for treating cancer that blocks the VEGFR-2 pathway; and other Adnectin therapies for the treatment of oncology, immunology, and cardiovascular diseases. Adnexus Therapeutics, Inc. was formerly known as Compound Therapeutics, Inc. and changed its name to Adnexus Therapeutics, Inc. in June 2006. The company was founded in 2002 and is headquartered in Waltham, Massachusetts. As of October 19, 2007, Adnexus Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Co.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.